ArticleBlood advances2025

Risk of synchronous and second primary malignancies in transplant-ineligible patients with multiple myeloma treated with lenalidomide.

Thomas Systchenko et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.